A Phase II Study of SKB571 in Patients With Lung Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2027-12-13
Target enrollment:
Participant gender:
Summary
This is a multicenter, phase II study. The purpose of this study is to evaluate the safety and preliminary anti-tumor activity of SKB571 in patients with advanced non-small cell lung cancer. Eligible subjects will receive SKB571 monotherapy, until radiographic disease progression, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.
Phase:
PHASE2
Details
Lead Sponsor:
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.